Liquid Biopsies – News and Features

University of Bristol research could lead to better detection of the most common type of malignant brain cancer.

Researchers have developed a new blood test that provides unprecedented insight into a patient’s cancer make-up, potentially allowing doctors to better select treatment options that will improve outcomes.

A new study has shown that a key genetic mutation that occurs early on in cancer alters RNA “dark matter” and causes the release of previously unknown RNA biomarkers.

UCF researchers have found a new way to track metastatic cancer cells in the body, which in the future could help identify cancer earlier and give patients more treatment options.

The liquid biopsy test, which uses two circulating proteins, was found to be highly accurate, sensitive and specific for both NASH and liver fibrosis.

Researchers have identified biomarkers for clear cell renal cell carcinoma and have developed a tool to indicate which patients are at high risk of poor outcomes.

Researchers have developed a novel, automated liquid biopsy test prototype, designed to detect cancer DNA in the blood of patients with advanced metastatic breast cancer within five hours.

Researchers have developed a liquid biopsy that can effectively determine if a patient with esophageal cancer will respond to certain treatments, potentially avoiding patients receiving unnecessary additional therapy.

A novel blood test that assesses levels of circulating tumor DNA can identify patients who require chemo after surgery.

A protein found in extracellular vesicles shed by tumor cells could be used as a liquid biopsy biomarker to better predict the success of immunotherapy for lung cancer patients.